申请人:Enanta Pharmaceuticals, Inc.
公开号:US20170333399A1
公开(公告)日:2017-11-23
The present invention provides compounds of Formula I:
and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these compounds and methods of using these compounds to treat or prevent a disease or disorder mediated by FXR. Specifically, the present invention relates to isoxazole derivatives useful as agonists for FXR and methods for their preparation and use.